| Literature DB >> 36213429 |
Imad A Alhaddad1, Ramzi Tabbalat2, Yousef Khader3, Zaid Elkarmi1, Zaid Dahabreh1, Ayman Hammoudeh4.
Abstract
Introduction: Studies that evaluate Middle Eastern patients who have long-term survival after coronary artery revascularization are scarce. The prevalence of diabetes mellitus (DM) is high and rapidly increasing in our region.Entities:
Keywords: Coronary artery bypass graft surgery; Middle East; coronary revascularization; diabetes mellitus; long-term survival; percutaneous coronary intervention
Year: 2022 PMID: 36213429 PMCID: PMC9542966 DOI: 10.4103/HEARTVIEWS.HEARTVIEWS_36_21
Source DB: PubMed Journal: Heart Views ISSN: 1995-705X
Baseline clinical characteristics at the time of the index coronary revascularization according to diabetes mellitus status
| Clinical feature | DM ( | No DM ( |
|
|---|---|---|---|
| Age at first coronary revascularization (years) | 53.9±8.75 | 53.0±9.82 | 0.164 |
| ≤45 | 51 (14.5) | 98 (18.1) | 0.578 |
| >45 | 300 (85.5) | 442 (81.9) | 0.196 |
| Coronary revascularization at baseline | |||
| PCI | 230 (65.5) | 369 (68.3) | 0.399 |
| CABG surgery | 121 (34.5) | 171 (31.7) | 0.426 |
| Years since the first coronary revascularization | 13.5±3.5 | 14.4±4.8 | 0.025 |
| 10 | 105 (29.9) | 149 (27.6) | 0.689 |
| 11-20 | 235 (67) | 339 (62.8) | 0.301 |
| >20 | 11 (3.1) | 52 (9.6) | <0.001 |
| Women | 69 (19.7) | 54 (10) | <0.001 |
| Hypertension | 249 (70.9) | 149 (27.6) | <0.001 |
| Dyslipidemia | 42 (12) | 28 (5.2) | <0.001 |
| Cigarette smoking | 157 (44.4) | 315 (58.3) | <0.001 |
| Family history of premature CAD | 30 (8.5) | 35 (6.5) | 0.252 |
CAD: Coronary artery disease, PCI: Percutaneous coronary intervention, CABG: Coronary artery bypass graft, DM: Diabetes mellitus
Emerging risk factors and cardiovascular events since the first coronary revascularization
| Event | DM, | No DM, |
|
|---|---|---|---|
| Emerging risk factors after the initial procedure | |||
| No DM initially developed DM | - | 167 (30.9) | - |
| Developed hypertension | 33 (9.4) | 107 (19.8) | <0.001 |
| Became smoker | 2 (0.6) | 3 (0.6) | 1.000 |
| Quit smoking | 70 (19.9) | 129 (23.9) | 0.519 |
| Cardiovascular events after the initial procedure | |||
| Acute coronary syndrome | 143 (40.7) | 225 (41.7) | 0.820 |
| Congestive heart failure | 44 (12.5) | 72 (13.3) | 0.511 |
| Stroke | 16 (4.6) | 32 (5.9) | 0.748 |
| Renal failure | 7 (2) | 19 (3.5) | 0.479 |
DM: Diabetes mellitus
Repeat coronary revascularization after the index procedure
| Procedure | DM, | No DM, |
|
|---|---|---|---|
| PCI | |||
| Total patients | 184 (52.4) | 246 (45.6) | |
| One occasion | 106 (30.2) | 152 (28.1) | 0.039 |
| Two occasions | 45 (12.8) | 71 (13.1) | |
| Three or more occasions | 33 (9.4) | 23 (4.3) | |
| CABG | |||
| Total patients | 25 (7.1) | 53 (9.8) | |
| One occasion | 25 (7.1) | 51 (9.4) | 0.202 |
| Two occasions | 0 | 2 (0.4) | |
| Three or more occasions | 0 | 0 |
PCI: Percutaneous coronary intervention, CABG: Coronary artery bypass graft, DM: Diabetes mellitus
Utilization of cardiometabolic medications at enrollment
| Medication | DM, | No DM, |
|
|---|---|---|---|
| Aspirin | 295 (92) | 449 (89.6) | 0.609 |
| Second antiplatelet agent | |||
| Clopidogrel | 124 (38.6) | 175 (34.9) | 0.023 |
| Ticagrelor | 16 (5) | 13 (2.6) | 0.081 |
| Beta-blocker | 257 (80) | 383 (76.4) | 0.192 |
| ACEI or ARB | 190 (54.1) | 292 (54) | 1.000 |
| Lipid-lowering agent | |||
| Statin | 287 (89.4) | 459 (91.4) | 0.355 |
| Fibrate | 9 (2.8) | 23 (4.6) | 0.327 |
| Ezitimibe | 3 (0.9) | 10 (2) | 0.935 |
| Combination | 3 (0.9) | 2 (0.4) | 0.948 |
ACEI: Angiotensin-converting enzyme inhibitor, ARB: Angiotensin receptor blocker, DM: Diabetes mellitus